Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BetterLife Pharma Inc. is a Canada-based biotechnology and pharmaceutical research company focused on the development of treatments for neurological and neuropsychiatric disorders. The company operates primarily within the biopharmaceutical research and development industry, with an emphasis on non-hallucinogenic psychedelic-derived compounds and other novel therapeutics targeting mental health and central nervous system conditions. BetterLife Pharma does not currently generate material commercial revenue and remains a development-stage company.
The company’s primary strategic focus has been the development of BETR-001, a non-hallucinogenic lysergamide compound being studied for the treatment of neuropsychiatric and neurodegenerative disorders. BetterLife Pharma positions itself as an early-stage innovator seeking to differentiate from traditional psychedelic companies by prioritizing compounds designed to avoid hallucinogenic effects. The company was founded in Canada and became publicly listed through capital markets to fund its research initiatives, evolving from an early biotech platform into a specialized CNS-focused drug development company.
Business Operations
BetterLife Pharma’s operations are centered on drug discovery and preclinical development, with activities including compound optimization, intellectual property development, and regulatory planning. The company does not operate manufacturing facilities and instead relies on third-party research organizations for laboratory work, formulation development, and preclinical studies. Its core assets are proprietary drug candidates and associated patents.
Operations are primarily based in Canada, with certain research activities and advisory relationships extending internationally through contracted research partners. The company does not report established commercial partnerships, joint ventures, or revenue-producing subsidiaries. All operational spending is directed toward research and development, general administration, and maintaining public company compliance.
Strategic Position & Investments
BetterLife Pharma’s strategy centers on advancing BETR-001 toward clinical development while exploring additional applications for non-hallucinogenic neurotherapeutics. Growth initiatives have historically focused on strengthening intellectual property, expanding preclinical data, and positioning the company for potential regulatory engagement. The company has disclosed intentions to pursue indications with significant unmet medical needs, particularly in neuropsychiatric disorders.
The company has not completed any large-scale acquisitions or material equity investments in external operating businesses. Its investment activity is largely internal, directed toward research programs and patent portfolios. Public disclosures indicate that progress timelines and long-term strategic outcomes remain subject to funding availability and regulatory developments, and certain development milestones have been delayed or revised over time based on capital constraints.
Geographic Footprint
BetterLife Pharma is headquartered in Canada, with its corporate and administrative functions centralized there. The company’s market presence is primarily limited to North America, where its shares trade on U.S. and Canadian public markets, and where it engages regulatory advisors and scientific consultants.
While BetterLife Pharma references global therapeutic markets in its strategic communications, it does not maintain physical operations, offices, or manufacturing assets outside Canada. Any international exposure is indirect and primarily related to outsourced research services or the potential future commercialization of drug candidates.
Leadership & Governance
BetterLife Pharma is led by executives with experience in biotechnology, finance, and public company management. Leadership has emphasized capital efficiency, intellectual property development, and cautious progression through the drug development pipeline given the company’s early-stage profile.
Key executives include:
- Ahmad Doroudian – Chief Executive Officer
- Elie Farah – Chief Financial Officer
- Dr. Gregory McKee – Director
- Daniel Del Gobbo – Director
Public disclosures indicate that governance is structured around a standard board and executive management model typical of small-cap biotechnology issuers. Specific long-term leadership philosophy statements beyond advancing shareholder value and clinical development objectives are limited in publicly available filings, and detailed succession planning information is not comprehensively disclosed.